Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1179 in Obese Participants
NCT07826364Phase 1Not yet recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-1179 in obesity (5 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Incidence of Adverse Events. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
SHR-1179
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07826364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07826364.